The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

The best value stocks have an attractive fundamental valuation, a healthy balance sheet, a stable or growing market share in ...

Merck (MRK) announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...